Last reviewed · How we verify
Gasmotin (MOSAPRIDE)
Mosapride works by enhancing acetylcholine release in the gastrointestinal tract, increasing motility.
Gasmotin, also known as Mosapride, is a small molecule drug that targets the 5-hydroxytryptamine receptor 4. It belongs to the drug class of mosaprides and works by enhancing acetylcholine release in the gastrointestinal tract, thereby increasing gastrointestinal motility. Mosapride is used to treat gastrointestinal disorders such as gastroesophageal reflux disease (GERD) and functional dyspepsia. However, its commercial status and approval indications are unclear. As a pharma professional, it is essential to note that Mosapride's safety profile and pharmacokinetic properties require further investigation.
At a glance
| Generic name | MOSAPRIDE |
|---|---|
| Drug class | mosapride |
| Target | Cytochrome P450 1A2, Cytochrome P450 2C19, Cytochrome P450 2C9 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Think of Mosapride like a messenger that helps the muscles in your stomach and intestines move food through your digestive system more efficiently. This helps to prevent symptoms like heartburn and bloating. By increasing the release of acetylcholine, a natural chemical that stimulates muscle contractions, Mosapride helps to speed up digestion and relieve discomfort.
Approved indications
Common side effects
- Hepatic function abnormal
- Interstitial lung disease
- Platelet count decreased
- Pneumonia aspiration
- Cerebral infarction
- Altered state of consciousness
- Decreased appetite
- Fatigue
- Ileus
- Upper respiratory tract inflammation
- Cardiac failure
- Aspartate aminotransferase increased
Key clinical trials
- Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia (PHASE4)
- Efficacy of Bacillus Coagulans in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia (PHASE4)
- The Effect of Two Prokinetics in Patients With Functional Dyspepsia (NA)
- A Comparative Evaluation of Mosapride Versus Metoclopramide for Enteral Feeding Intolerance in Critically Ill Patients (PHASE3)
- A Phase Ⅱ Study of Mosapride Citrate Injection in the Treatment of Postoperative Gastrointestinal Dysfunction (PHASE2)
- Effect of Mosapride Citrate on Gastrointestinal Motility After Laparoscopic Gastrectomy (NA)
- Zuojin Wan Combined With Rabeprazole or Mosapride for the Treatment of Functional Dyspepsia Combined With Depression (NA)
- Deep Needling at Zhongliao Point to Stimulate the Sacral Nerve for the Treatment of Slow Transit Constipation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gasmotin CI brief — competitive landscape report
- Gasmotin updates RSS · CI watch RSS